|
CA2216844A1
(en)
*
|
1995-03-31 |
1996-10-03 |
Drug Delivery System Institute, Ltd. |
Amidite derivatives and oligonucleotide derivatives
|
|
US5855911A
(en)
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
|
DE19631189A1
(de)
*
|
1996-08-02 |
1998-02-05 |
Max Delbrueck Centrum |
Neuartige kationische Amphiphile für den liposomalen Gentransfer
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
|
GB2372502B
(en)
*
|
2000-12-12 |
2004-10-13 |
Imperial College |
Carbohydrate compounds containing cholesterol and their use
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
PH12012501596A1
(en)
|
2010-02-24 |
2017-02-03 |
Arrowhead Res Corporation |
Compositions for targeted delivery of sirna
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
RU2013117288A
(ru)
|
2010-12-17 |
2015-01-27 |
Эрроухэд Рисерч Корпорейшн |
СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
CA2842039A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
US20140100178A1
(en)
*
|
2012-10-04 |
2014-04-10 |
Aslam Ansari |
Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
|
|
CA2889044A1
(en)
|
2012-11-15 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
CA2893801A1
(en)
|
2013-01-30 |
2014-08-07 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotide carbohydrate conjugates
|
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
|
MX367083B
(es)
|
2013-06-27 |
2019-08-05 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
MX2017011422A
(es)
|
2015-03-17 |
2017-11-10 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen del factor xii.
|
|
CN115957337A
(zh)
|
2015-08-07 |
2023-04-14 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
JOP20170057B1
(ar)
|
2016-03-07 |
2022-03-14 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة كمركبات علاجية
|
|
CA3013683C
(en)
|
2016-03-14 |
2021-07-13 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for reduction of pd-l1 expression
|
|
EP3228326A1
(de)
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleinsäure verbunden mit einem dreiwertigen glykokonjugat
|
|
AU2017285350A1
(en)
|
2016-06-17 |
2018-12-20 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
JOP20170056B1
(ar)
|
2016-09-02 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة
|
|
US10450565B2
(en)
|
2017-01-10 |
2019-10-22 |
Arrowhead Pharmaceuticals, Inc. |
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
|
|
CN110234326B
(zh)
|
2017-01-30 |
2024-11-12 |
箭头药业股份有限公司 |
用于抑制因子xii基因表达的组合物和方法
|
|
EP3385272A1
(de)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Weitere neuartige oligonukleotid-ligand-konjugate
|
|
WO2018185253A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Ligand modified double-stranded nucleic acids
|
|
EP3483269A1
(de)
|
2017-11-13 |
2019-05-15 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
EP3385381A1
(de)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
EP4219714A3
(de)
|
2017-04-05 |
2023-08-30 |
Silence Therapeutics GmbH |
Rna-interferenz-vermittelte hemmung von tmprss6
|
|
EP3385380A1
(de)
|
2017-04-05 |
2018-10-10 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
US11015198B2
(en)
|
2017-04-05 |
2021-05-25 |
Silence Therapeutics Gmbh |
Products and compositions
|
|
WO2018185252A1
(en)
|
2017-04-05 |
2018-10-11 |
Silence Therapeutics Gmbh |
Nucleic acid conjugates
|
|
EP3550022A1
(de)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
IL269517B2
(en)
|
2017-04-05 |
2025-01-01 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
MX2020001912A
(es)
|
2017-09-14 |
2020-03-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
|
|
KR20200030594A
(ko)
|
2017-10-16 |
2020-03-20 |
에프. 호프만-라 로슈 아게 |
B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
|
|
CN111212909A
(zh)
|
2017-10-17 |
2020-05-29 |
箭头药业股份有限公司 |
用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
|
|
EP3483270A1
(de)
|
2017-11-13 |
2019-05-15 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
CN119120476A
(zh)
|
2017-11-13 |
2024-12-13 |
赛伦斯治疗有限责任公司 |
用于抑制细胞中lpa的表达的核酸
|
|
SG11202003082UA
(en)
|
2017-11-13 |
2020-05-28 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
|
WO2019092282A1
(en)
|
2017-11-13 |
2019-05-16 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of aldh2 in a cell
|
|
US11560563B2
(en)
|
2018-04-05 |
2023-01-24 |
Silence Therapeutics Gmbh |
SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
|
|
EP3550021A1
(de)
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen für die inhibierung der expression eines zielgens
|
|
TWI862501B
(zh)
|
2018-07-03 |
2024-11-21 |
瑞士商赫孚孟拉羅股份公司 |
用於調制 Tau 表現之寡核苷酸
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
EP3598995A1
(de)
|
2018-07-26 |
2020-01-29 |
Silence Therapeutics GmbH |
Produkte und zusammensetzungen
|
|
US20220160870A1
(en)
|
2018-08-28 |
2022-05-26 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
US12534728B2
(en)
|
2018-09-19 |
2026-01-27 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
|
|
AU2019380628B2
(en)
|
2018-11-13 |
2024-10-31 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of LPA in a cell
|
|
WO2020104669A1
(en)
|
2018-11-23 |
2020-05-28 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
|
EP3730617A1
(de)
|
2019-04-26 |
2020-10-28 |
Silence Therapeutics GmbH |
Nukleinsäure zur hemmung der expression von c3 in einer zelle
|
|
TWI872048B
(zh)
|
2019-02-07 |
2025-02-11 |
美商艾羅海德製藥公司 |
用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
WO2020225301A1
(en)
|
2019-05-07 |
2020-11-12 |
Universität Bern |
Nucleic acids for inhibiting expression of pros1 in a cell
|
|
AU2020286462B2
(en)
|
2019-06-06 |
2026-07-02 |
Arrowhead Pharmaceuticals, Inc. |
Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
|
|
JP2022536945A
(ja)
|
2019-06-18 |
2022-08-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
|
|
WO2021037941A1
(en)
|
2019-08-27 |
2021-03-04 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
|
EP4081217A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination von antivirusmitteln, die hbv und/oder einen immunmodulator zur behandlung von hbv steuern
|
|
EP4081639A1
(de)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmazeutische kombination eines therapeutischen oligonucleotids gegen hbv und eines tlr7-agonisten zur behandlung von hbv
|
|
MX2022009419A
(es)
|
2020-01-31 |
2022-08-25 |
Avilar Therapeutics Inc |
Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
|
|
KR20220158011A
(ko)
|
2020-03-26 |
2022-11-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
|
|
EP4158023A1
(de)
|
2020-05-27 |
2023-04-05 |
Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE |
Nukleinsäuren zur hemmung der expression von cnnm4 in einer zelle
|
|
WO2022060721A2
(en)
|
2020-09-15 |
2022-03-24 |
Arrowhead Pharmaceuticals, Inc. |
Methods for the reduction of z-aat protein levels
|
|
CA3197198A1
(en)
|
2020-11-04 |
2022-05-12 |
Ute SCHAEPER |
Nucleic acids for inhibiting expression of pros1 in a cell
|
|
WO2022184852A1
(en)
|
2021-03-03 |
2022-09-09 |
Silence Therapeutics Gmbh |
Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
|
|
WO2022223557A1
(en)
|
2021-04-20 |
2022-10-27 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of xdh in a cell
|
|
WO2022229150A1
(en)
|
2021-04-27 |
2022-11-03 |
Silence Therapeutics Gmbh |
Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders
|
|
US11629349B2
(en)
|
2021-06-21 |
2023-04-18 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
|
|
US20250136977A1
(en)
|
2021-09-02 |
2025-05-01 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2024126687A1
(en)
|
2022-12-16 |
2024-06-20 |
Silence Therapeutics Gmbh |
Nucleic acids conjugated to an albumin binding moiety
|
|
EP4684015A2
(de)
|
2023-03-21 |
2026-01-28 |
Arrowhead Pharmaceuticals, Inc. |
Rnai-mittel zur hemmung der expression des komplementfaktors b (cfb), pharmazeutische zusammensetzungen daraus und verfahren zur verwendung
|
|
AU2024331015A1
(en)
|
2023-08-30 |
2026-02-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
|
|
WO2025072748A2
(en)
|
2023-09-29 |
2025-04-03 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2025132845A1
(en)
|
2023-12-21 |
2025-06-26 |
Silence Therapeutics Gmbh |
Galnac phosphoramidites and their uses
|
|
AU2025214336A1
(en)
|
2024-01-29 |
2026-07-23 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of gpr146 in a cell
|
|
WO2025163186A1
(en)
|
2024-02-01 |
2025-08-07 |
Silence Therapeutics Gmbh |
Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell
|
|
US20250333742A1
(en)
|
2024-04-25 |
2025-10-30 |
Insitro, Inc. |
Compositions and methods for treating metabolic dysfunction-associated steatotic liver disease
|
|
WO2026044017A2
(en)
|
2024-08-21 |
2026-02-26 |
Insitro, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease
|
|
WO2026132332A2
(en)
|
2024-12-18 |
2026-06-25 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of inhbe in a cell
|
|
WO2026130744A1
(en)
|
2024-12-19 |
2026-06-25 |
Silence Therapeutics Gmbh |
Nucleic acids comprising locked nucleic acids (lna) for inhibiting gene expression in a cell
|